

Sun Pharmaceutical Industries Ltd.
17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
Tel.: (91-22) 6645 5645
Fax.: (91-22) 6645 5685



FOR IMMEDIATE RELEASE

Sun Pharma acquires URL generic business from Takeda

Mumbai, December 17, 2012: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BODRA, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced today that Caraco Pharmaceutical Laboratories, Ltd. (Caraco), its wholly-owned subsidiary, has entered into a definitive agreement with Takeda Pharmaceuticals U.S.A., Inc, a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, to buy the URL Pharma, Inc.* generic business.

Upon completion of the purchase, the non-Colcrys (colchicine, USP) generic assets of URL Pharma will be owned and managed by Caraco. The deal is subject to satisfaction of customary closing conditions, including applicable regulatory approvals.

** Former privately-held Philadelphia-based pharmaceutical company acquired by Takeda America Holdings, Inc. (TAH) in June 2012.*

About Sun Pharma

Established in 1983, listed since 1994 and headquartered in India, Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics and ophthalmology. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

Contacts

Mira Desai

Tel +91 22 6645 5645, Xtn 606
Tel Direct +91 22 66455606
Mobile +91 98219 23797
E mail mira.desai@sunpharma.com